CME — CME Group
Boring market plumbing that quietly prints money when everyone else is panicking
CME is the boring market plumbing behind futures and derivatives across rates, equity indexes, commodities and FX. The moat is liquidity. People trade where everyone else already trades, which attracts more people, which makes the whole thing annoyingly hard to dislodge.
CME makes basically zero attempt to be sexy, which honestly makes me like it more. People still need to hedge rates, commodities, equity indexes and currencies. CME owns the marketplace and the clearing infrastructure.
Why I care about this one
The moat is liquidity. Traders go where the liquidity already is, which creates more liquidity, which makes everyone else want to go there too. Clearing, capital efficiency, data and benchmark contracts all reinforce it. The nice part is I do not need to correctly predict the next macro panic to benefit from people needing the venue.
Q2 2026 average daily volume was 29.8M contracts, market-data revenue hit a record $238M, and CME highlighted more than $95B of daily margin efficiencies for clients. That is the boring infrastructure doing exactly what I want it to do.
CME makes money from liquidity and clearing, not from some heroic unit-growth story. Volume moves around with the market environment, sure. The useful part is that the network can get stronger while customers keep concentrating their hedging and trading in the same contracts.
Q2 2026
Primary sources: Q2 2026 results ↗
Q2 was mostly confirmation: $1.7B of revenue, 29.8M average daily volume and record $238M of market-data revenue. The liquidity/network thesis is the same. The entry framework now derives directly from the $12.70 normalized EPS anchor at 22x / 19.5x / 18x.
Structural hedging demand keeps lifting volumes across asset classes, market-data economics deepen, and new products add growth without needing balance-sheet risk or acquisition gymnastics.
Liquidity genuinely migrates elsewhere, regulation damages contract or clearing economics, a long low-volatility period exposes weaker organic growth than I expect, or management decides excess cash needs an empire.
What gets this into the portfolio
Valuation & scenario math
My bands are 22x / 19.5x / 18x P/E, eventual target 2%–4%. A move through those levels changes the opportunity, not the business thesis. Fine by me. There are plenty of other things I can do with money while I wait.
I am not asking CME to grow like a software company. That means the entry multiple has to do more of the work. Modest earnings growth plus durable network economics is great if I do not pay so much for the durability that I kill the return myself.
“My current view” is the output of my dated valuation framework, not a magical buy instruction. A BUY still has to beat the expected return of what I already own and the index before it gets actual money.
22x / 19.5x / 18x normalized earnings
| Band | Buy price | 5Y base center | 5Y CAGR at entry |
|---|---|---|---|
| Starter | $279 | $410 | +8.0% |
| Normal | $248 | $410 | +10.6% |
| Aggressive | $229 | $410 | +12.3% |
The zone label uses the live quote when available; the model itself is anchored to the Sep 28, 2026 reference close at $264. I am willing to accept a lower return hurdle here than for a fast grower because the risk/return profile is genuinely different. That is not permission to pay any multiple I feel like.
This is intentionally a boring earnings model for a boringly good market-infrastructure business. I am paying for durable liquidity and data economics, not trying to invent a hypergrowth story that is not there.
| Normalized EPS today | $12.70 |
| Annual EPS growth | 7% |
| EPS by Sep 25, 2031 | ~$17.81 |
| Terminal P/E | 23x |
| Implied base price | ~$410/share |
The base case is basically ~$17.81 of Sep 25, 2031 EPS at 23x, or about $410/share. Same math, just without making the reader decode equation soup.
| Case | What has to be true | Target range | Total return* | Annualized return* |
|---|---|---|---|---|
| Bear | 3% annual EPS growth · 18x terminal P/E. Lower volatility and rate normalization soften volume while the defensive premium compresses. | $246–$284 center ~$265 | +0.2% | +0.0% |
| Base | 7% annual EPS growth · 23x terminal P/E. Volumes, market data and product breadth compound steadily while the liquidity/network moat remains intact. | $381–$438 center ~$410 | +54.9% | +9.1% |
| Bull | 10% annual EPS growth · 26x terminal P/E. Structural hedging demand and product expansion support above-trend earnings growth without requiring a heroic terminal multiple. | $495–$569 center ~$532 | +101.1% | +15.0% |
*The static returns use the dated reference price. The annualized figure on the live page also refreshes from the current quote. For shorter model horizons, annualizing can make the number look ridiculous, so I care about total return and the underlying milestones at least as much.
Capital allocation
Boring capital allocation for a business that should be boring. Perfect.
CME can invest in the exchange, clearing and product depth it actually needs and then send a lot of excess cash back to shareholders. The discipline is the feature. I do not need management proving how imaginative it can be with the balance sheet.
Stage-relative, not some objective rating-agency grade. The number is there to force the judgment into the open. See the rubric →
What management is actually doing with the cash
I really do not need creativity from management here. Keep the infrastructure resilient, deepen the contracts and clearing network, and return the cash the business does not need. The dumb version of capital allocation would be using a beautiful cash-generating network to go buy mediocre growth somewhere else.
What earns another dollar from me
No position. I would like one eventually, especially as a different factor exposure from my tech-heavy portfolio, but diversification is not a reason to accept a bad expected return.
What can break this
Volumes are cyclical, regulation matters, competition exists, and a quiet market can make the growth profile look boring. Fine. The risk I care more about is paying so much for defensive quality that I end up with a low-teens return anyway.
If liquidity migrates, regulatory changes permanently damage contract economics, or the clearing/data moat erodes, the business quality assumption changes.
CME is exactly the kind of company I can watch for a stupidly long time without feeling any need to force a position. If the price eventually cooperates, great.